NBIX
$130.71
Neurocrine Biosciences, Inc.
Recent News
A Look At Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Pullback
Recent share performance and business snapshot Neurocrine Biosciences (NBIX) has drawn attention after a recent pullback, with the stock showing a 0.1% decline over the past day and an 8% decline over the past month. Over the past 3 months, the share price shows a 16.6% decline, while the 1 year total return stands at 21.1% and the 3 year total return at 36%. The 5 year total return is 37.3%. The company last closed at US$129.86 and reports annual revenue of US$2.86b and net income of...
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Blackstone, Blue Owl Capital, Booking Holdings, Cheniere Energy, Comcast, Domino’s Pizza, KeyCorp, Qualcomm, and More
Pre-Market Stock Futures: Futures are trading higher this morning after a dreadful day to start the trading week. Various reasons were cited for the risk-off bias on Monday, but the tariff situation, which the President raised to 15% from 10% over the weekend after the Supreme Court struck it down last Friday, was one of ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: Blackstone, Blue Owl Capital, Booking Holdings, Cheniere Energy, Comcast, Domino’s Pizza, KeyCorp, Qualcomm, and M
Truist Lowers Neurocrine Biosciences, Inc.’s (NBIX) PT Following 2026 Outlook Update
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is among the 7 Oversold Pharma Stocks to Buy Now. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the most oversold stocks. TheFly reported on February 17 that Truist reduced its price target on NBIX to $140 from $169 and maintained a Buy rating on the stock. The increase came after management’s 2026 projection, and the company’s fourth-quarter results were […]
Is It Time To Reassess Neurocrine Biosciences (NBIX) After Recent Share Price Weakness
If you are wondering whether Neurocrine Biosciences is offering good value at its current share price, this breakdown will help you see what the numbers are really saying. The stock last closed at US$128.63, with returns of 3.6% over 7 days, a 5.5% decline over 30 days, an 8.5% decline year to date, and a 6.6% gain over 1 year, plus longer term returns of 25.6% over 3 years and 17.5% over 5 years. Recent attention around Neurocrine Biosciences has focused on its position in the...
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data
This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.